Special Issue

Cellular Immune Responses in Diseases

Message from the Guest Editor

Cellular immune responses are a crucial aspect of the immune system's defence mechanism, maintaining the right balance between protection and auto-control to avoid damaging healthy tissues or inducing chronic inflammation. In general, these responses involve innate and adaptive mechanisms, like phagocytosis and cell-mediated cytotoxicity, engaging different leukocyte subpopulations, both antigen-specific and antigen-nonspecific cells. Antigen-specific cellular responses are orchestrated by T cells, crucial for the capacity of the organism to distinguish self from nonself. A good example is the rejection of a graft by lymphoid cells as well as graft-versus-host disease. One T cell has subpopulations of cytotoxic effector cells, which can lyse virus-infected or malignant cells. The subpopulations of helper T cells (e.g., Th1, Th2, Th17) have different patterns of effector cytokine-dependent functions after antigen recognition. An imbalance in the cellular immune system can lead to various conditions. We expect that this Special Issue will provide fresh perspectives in the integration of knowledge concerning cellular immune responses and their regulation in disease contexts.

Guest Editor

Dr. Mafalda Fonseca

Health Sciences Research Centre, University of Beira Interior (CICS-UBI), 6200-506 Covilhã, Portugal

Deadline for manuscript submissions

closed (30 June 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/180813

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).